Recombinant Collagen: Companies, Startups & Research

Jiangsu Trautec Medical Technology Co. and Shanxi Jinbo Bio Pharmaceutical Co. are notable participants, with 65 and 32 recent-window documents, respectively. Trautec works on high-stability collagen, hydrogels and wound-repair materials; Jinbo develops biosynthetic human type IV collagen and holds sequence and preparation patents. Hui Kang Zhiyuan Medical Devices(Xi'an) Co., Ltd. is another active patenting company, with recent gel and filler filings.

Cellbricks Therapeutics and Phoenix Tissue Repair are two named startups, with 2 and 4 recent-window documents, respectively. Cellbricks develops recombinant human collagen for light-based bioprinting and investigates yeast-based production. Phoenix Tissue Repair is developing recombinant type VII collagen compositions and production systems for dystrophic epidermolysis bullosa. The available information identifies their technical focus but is not enough to rank their commercial prospects.

University of Sichuan and Northwest University, China are prominent research organizations, with 74 and 42 recent-window documents, respectively. University of Sichuan researchers report collagen hydrogels for wound healing and cartilage repair. Northwest University studies type IV collagen and has optimized type III collagen expression in Komagataella phaffii. Chinese Academy of Sciences CAS is also active in hydrogel research for regeneration and wound repair.

The recorded grant data lists $1,705,623 across 6 grants since 2020. These figures describe grants associated with the topic, not a complete measure of private investment or company financing. The available records do not identify a dedicated public funding program, so the grant total should not be treated as the field’s full funding level.

Shanxi Jinbo Bio Pharmaceutical Co. leads the listed patent holders with 13 patents, followed by Hui Kang Zhiyuan Medical Devices(Xi'an) Co., Ltd. with 10. The topic has 198 patents in the 24-month window, while patent activity declined 24.8% in the latest 12 months compared with the previous 12 months. Recent filings include collagen gel materials and stability-focused sequence designs.

The main approaches are bacterial expression, yeast and fungal expression, plant expression, and mammalian cell production. Mammalian systems can support complex protein processing but are more demanding to scale. Microbial hosts can offer efficient production, though collagen folding and post-translational modifications require attention. Plant expression is another route, with consistency and downstream processing among the practical considerations.

Wound care accounts for 614 documents, while tissue engineering and regenerative medicine account for 591. Other tracked uses include cell culture and bioprocessing, cosmetics and aesthetics, and dental applications. Recent work also explores soft-tissue filling, osteochondral regeneration, wound-healing hydrogels and skin delivery. The material’s sequence and format can be tailored to the biological and mechanical needs of an application.

The United States leads with 3,263 documents, followed by China with 2,670. The United Kingdom has 949 and Germany 929. These figures show substantial activity across both research and company settings, but document counts do not measure product maturity or manufacturing capacity. China is prominent among the listed patent holders and research organizations.

In September 2026, Jinan University reported injectable hydroxyapatite-reinforced type III collagen microgels for soft-tissue filling, and a Naval Medical University-led study reported a photocrosslinkable type XVII collagen hydrogel for osteochondral regeneration. In October 2026, Jiangsu Trautec patented a high-stability collagen design. News also reported a BASF and Bota Biosciences collagen III launch in July 2026 and a CollPlant bioprinting kit launch in March 2026.